Indaptus Therapeutics appoints Yu Ding as CFO, Qinglai Lu to board; CFO Nir Sassi resigns

Indaptus Therapeutics, Inc.

Nir Sassi resigned as CFO effective April 1, 2026; resignation not due to disagreement.
Yu Ding appointed CFO effective April 1, 2026; brings experience from Grand Auto Service and Hong Kong listed firms.
Qinglai Lu appointed to Board of Directors effective April 8, 2026; deemed independent.
Qinglai Lu also appointed to Audit Committee along with Jerome Jabbour; Matthew McMurdo resigned from Audit Committee.
New CFO Yu Ding has over 20 years experience in financial planning, capital management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.